This week's research brings fresh hope — scientists are finding new ways to protect lung cells, stop scarring at its source, and a computer-tested drug combination showed it might keep lung function significantly more stable than current treatments alone.
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
Researchers made progress on several fronts this week. A drug called PLN-74809 finished a mid-stage trial and slowed the loss of lung capacity in IPF patients — that is genuinely exciting news. Scientists also learned that certain stem cells (the body's repair workers) get stuck in a broken state in scarred lungs, and that a natural protein called R-spondin helps keep lung repair cells alive. Another study showed that fat-storing cells in the lung lose their healthy identity in IPF, which may explain why scarring keeps spreading. Understanding why repair fails is the first step to fixing it.
A computer AI tested many drug combinations and found one that could keep lung capacity (FVC — a measure of how much air you can breathe out) at 64%. For context, most untreated IPF lungs decline steadily over time, so holding at 64% would represent meaningful stability for many patients. The combination included existing drugs plus newer experimental ones targeting scarring and cell aging.
One question to ask your lung doctor at your next visit: 'Have you heard about the PLN-74809 trial results, and could a dual integrin blocker — a drug that cuts off two signals that cause scarring — be something worth exploring for me?'